Cizzle Biotechnology

Executive Summary

Cizzle Biotechnology is a UK-based diagnostics company developing a blood-based test for the early detection of lung cancer. The company's proprietary technology aims to provide a cost-effective alternative to current screening methods, such as low-dose CT scans, which are expensive, expose patients to radiation, and require repeated scans for monitoring. By identifying biomarkers associated with early-stage lung cancer, Cizzle's test could enable earlier intervention, improve survival rates, and reduce healthcare costs. The company's approach targets a significant unmet need: lung cancer is the leading cause of cancer death worldwide, and early detection remains challenging due to the lack of sensitive, non-invasive screening tools. If successful, Cizzle's test could be adopted in routine clinical practice for high-risk populations, such as smokers and individuals with a family history of lung cancer. The company has not yet commercialized a product, but its focus on a scalable, low-cost solution positions it well in the growing liquid biopsy market. With over 15 years of research, Cizzle aims to validate its technology through clinical studies and regulatory approvals.

Upcoming Catalysts (preview)

• Q3 2026Completion of clinical validation study for lung cancer detection test65% success
• Q4 2026Partnership or licensing agreement with a diagnostic or pharmaceutical company50% success
• Q1 2027Regulatory submission for CE marking or UKCA approval60% success